T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: t2biosystems.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2022 | $0.70 | Neutral → Buy | Alliance Global Partners |
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
NT 10-K - T2 Biosystems, Inc. (0001492674) (Filer)
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
SCHEDULE 13G/A - T2 Biosystems, Inc. (0001492674) (Subject)
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
DEF 14A - T2 Biosystems, Inc. (0001492674) (Filer)
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
PRE 14A - T2 Biosystems, Inc. (0001492674) (Filer)
8-K - T2 Biosystems, Inc. (0001492674) (Filer)
Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e
LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin will join the Company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Mr. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S. "We are thrilled to have Brett join T2 Biosystems as Chief Commercial Officer," said John Sperzel, Chairman and CEO at T2
LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. "We are excited to have Laura join the T2 Biosystems Board of Directors," said John Sperzel, Chairman and CEO at T2 Biosystems. "Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory." Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing lead
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company's Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience working with and advising private and public life sciences companies. "We are excited to welcome Darlene to our Board of Directors at this important time in our company," said David de Graaf, Chief Executive Officer of Abcuro. "Darlene brings an impressive, thirty-year track record working with both publicly traded and venture-backed life
LEXINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. In her new role, Dr. Ahuja will act as the company’s key medical spokesperson providing leadership and strategic direction for all medical, clinical and scientific affairs activities for T2 Biosystems. “I am excited to be joining the T2 Biosystems leadership team at this critical time when high-quality rapid diagnostics – especially for sepsis – are growing in importance as we continue to face mounting
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
4 - T2 Biosystems, Inc. (0001492674) (Issuer)
LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the second quarter ended June 30, 2024. Recent Financial and Operational Highlights Achieved second quarter 2024 total revenue of $2.0 million, all from sepsis product sales.Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods, led by T2Bacteria® and T2Resistance® panel sales.Executed contracts for 2 T2Dx® Instruments during the second quarter, both fr
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced unaudited financial and operational results for the first quarter ended March 31, 2024. Recent Financial and Operational Highlights Achieved first quarter 2024 sepsis product revenue of $2.1 million, representing growth of 25% compared to the prior year period and sequential growth of 23% compared to the fourth quarter of 2023, led by T2Candida Panel sales and strong T2Resistance Panel sales internationally.Executed contracts for 8 T2Dx® Instruments during the first quarter, inclu
LEXINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close on Monday, May 6, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US
LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates. Recent Highlights Announced plans to commercialize the T2Lyme Panel in the third quarter of 2024 as a laboratory developed test (LDT) without the need to be run on the T2Dx® Instrument providing throughput improvements and cost of goods advantages. The Company is currently in discussions with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506
LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023. Full Year 2023 and Recent Commercial Highlights Achieved full year 2023 total revenue of $7.2 million, including sepsis and related product revenue of $6.8 million and research and contribution revenue of $0.4 million.Achieved fourth quarter 2023 total revenue of $1.7 million, comprised entirely of product revenue including record sales of the T2Bacteria Panel in
LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including
LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st
LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (
LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel and the T2Candida® Panel, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood. "We are pleased to extend our multi-year agreement with Vizient, the nati
LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Biosystems' proprietary technology is a key component of its FDA-cleared products, including the first and only products able to detect sepsis-causing pathogens directly from whole blood. T2 Biosystems' expanded business model is intended to generate non-dilutive capital through licensing agreements that provide access to the Company's patente
LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the
LEXINGTON, Mass. and SCHENECTADY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, and Prxcision, Inc., innovators behind the real-time AI-powered decision support platform pRxcision®, have announced a co-marketing collaboration intended to deliver a revolutionary solution for patients suspected of bloodstream infections and sepsis, and combat the escalating crisis of antibiotic resistance. Antibiotic resistance is one of the greatest threats facing modern medicine, with millions of lives at risk. Over 1.27 million deaths are reported annually due to antimicrobial res
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE:CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems' FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® Instrument, the T2Bacteria® Panel, and the T2Candida® Panel. "We are thrilled to have entered into a distribution agreement with Cardinal Health that will make them the exclusive distrib
Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70
Alliance Global Partners resumed coverage of T2 Biosystems with a rating of Neutral and set a new price target of $1.65 from $2.40 previously
Alliance Global Partners downgraded T2 Biosystems from Buy to Neutral and set a new price target of $2.40 from $2.60 previously
SVB Leerink reiterated coverage of T2 Biosystems with a rating of Outperform and set a new price target of $3.00 from $4.00 previously
SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G/A - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G/A - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13D/A - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13D/A - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13D - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)
SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)